Jürgen Kurt Rockstroh

Summary

Affiliation: University of Bonn
Country: Germany

Publications

  1. ncbi request reprint Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy
    M Lichterfeld
    Department of General Internal Medicine, University of Bonn, Berlin, Germany
    HIV Med 3:37-43. 2002
  2. pmc Review of tipranavir in the treatment of drug-resistant HIV
    Hendrik Streeck
    Department of Medicine I, University of Bonn Bonn, Germany
    Ther Clin Risk Manag 3:641-51. 2007
  3. ncbi request reprint [Hepatitis C and HIV coinfection. Current aspects of therapy]
    J K Rockstroh
    Universitätsklinik und Poliklinik I, Universitatsklinikum Bonn
    MMW Fortschr Med 144:30-2. 2002
  4. ncbi request reprint Management of hepatitis C/HIV coinfection
    Jurgen K Rockstroh
    Department of Medicine I, University of Bonn, Bonn, Germany
    Curr Opin Infect Dis 19:8-13. 2006
  5. ncbi request reprint Influence of viral hepatitis on HIV infection
    Jürgen Kurt Rockstroh
    Department of Medicine I, University of Bonn, Sigmund Freud Str 25, D 53105 Bonn, Germany
    J Hepatol 44:S25-7. 2006
  6. ncbi request reprint [HIV-infection: modern antiretroviral therapy]
    J K Rockstroh
    Medizinische Universitätsklinik und Poliklinik I, Universitat Bonn
    Dtsch Med Wochenschr 129:1921-4. 2004
  7. ncbi request reprint HIV and hepatitis C virus co-infection
    Jürgen Kurt Rockstroh
    HIV Outpatient Clinic, and Department of Medicine I, University of Bonn, Bonn, Germany
    Lancet Infect Dis 4:437-44. 2004
  8. ncbi request reprint [Antiretroviral treatment of HIV infected patients]
    Mathias Lichterfeld
    Immunologische Ambulanz, Medizinische Klinik I, Rheinischen Friedrich Wilhelms Universität, Sigmund Freud Strasse 25, 53105 Bonn
    Med Monatsschr Pharm 26:111-21; quiz 121-2. 2003
  9. ncbi request reprint Management of hepatitis B and C in HIV co-infected patients
    Jürgen Kurt Rockstroh
    University of Bonn, Bonn, Germany
    J Acquir Immune Defic Syndr 34:S59-65. 2003
  10. ncbi request reprint Clinical perspective of fusion inhibitors for treatment of HIV
    J K Rockstroh
    Department of Medicine I, University of Bonn, Bonn, Germany
    J Antimicrob Chemother 53:700-2. 2004

Detail Information

Publications58

  1. ncbi request reprint Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy
    M Lichterfeld
    Department of General Internal Medicine, University of Bonn, Berlin, Germany
    HIV Med 3:37-43. 2002
    ....
  2. pmc Review of tipranavir in the treatment of drug-resistant HIV
    Hendrik Streeck
    Department of Medicine I, University of Bonn Bonn, Germany
    Ther Clin Risk Manag 3:641-51. 2007
    ..This review summarizes the currently available data and studies on tipranavir and discusses the possible position of tipranavir in the currently available armamentarium of antiretroviral drugs...
  3. ncbi request reprint [Hepatitis C and HIV coinfection. Current aspects of therapy]
    J K Rockstroh
    Universitätsklinik und Poliklinik I, Universitatsklinikum Bonn
    MMW Fortschr Med 144:30-2. 2002
    ....
  4. ncbi request reprint Management of hepatitis C/HIV coinfection
    Jurgen K Rockstroh
    Department of Medicine I, University of Bonn, Bonn, Germany
    Curr Opin Infect Dis 19:8-13. 2006
    ..Therefore, treatment strategies for management of hepatitis C coinfection in HIV-infected individuals are urgently needed...
  5. ncbi request reprint Influence of viral hepatitis on HIV infection
    Jürgen Kurt Rockstroh
    Department of Medicine I, University of Bonn, Sigmund Freud Str 25, D 53105 Bonn, Germany
    J Hepatol 44:S25-7. 2006
    ..There is, however, an increased risk of liver disease related morbidity and mortality as well as more hepatoxicity under antiretroviral treatment regimens...
  6. ncbi request reprint [HIV-infection: modern antiretroviral therapy]
    J K Rockstroh
    Medizinische Universitätsklinik und Poliklinik I, Universitat Bonn
    Dtsch Med Wochenschr 129:1921-4. 2004
  7. ncbi request reprint HIV and hepatitis C virus co-infection
    Jürgen Kurt Rockstroh
    HIV Outpatient Clinic, and Department of Medicine I, University of Bonn, Bonn, Germany
    Lancet Infect Dis 4:437-44. 2004
    ..Owing to the high rates of HIV and HCV co-infection worldwide, new improved treatment strategies and guidelines for the management of co-infection remain a major future goal...
  8. ncbi request reprint [Antiretroviral treatment of HIV infected patients]
    Mathias Lichterfeld
    Immunologische Ambulanz, Medizinische Klinik I, Rheinischen Friedrich Wilhelms Universität, Sigmund Freud Strasse 25, 53105 Bonn
    Med Monatsschr Pharm 26:111-21; quiz 121-2. 2003
  9. ncbi request reprint Management of hepatitis B and C in HIV co-infected patients
    Jürgen Kurt Rockstroh
    University of Bonn, Bonn, Germany
    J Acquir Immune Defic Syndr 34:S59-65. 2003
    ..The high number of HIV/HCV and HIV/HBV co-infections, as well as the much more unfavorable course of HBV and HCV in these patients, underlines the need to establish treatment strategies for HBV and HCV in HIV co-infected individuals...
  10. ncbi request reprint Clinical perspective of fusion inhibitors for treatment of HIV
    J K Rockstroh
    Department of Medicine I, University of Bonn, Bonn, Germany
    J Antimicrob Chemother 53:700-2. 2004
    ..In this article, the characteristics and clinical perspectives of fusion inhibitors are presented and discussed...
  11. ncbi request reprint Therapy of hepatitis C in HIV-coinfection
    J K Rockstroh
    Medizinische Universitatsklinik I, Sigmund Freud Strasse 25, D 53105 Bonn, Germany
    Eur J Med Res 9:304-8. 2004
    ....
  12. ncbi request reprint [HIV and hepatitis coinfection]
    P Ingiliz
    Medizinische Universitätsklinik 1, Bonn
    Dtsch Med Wochenschr 130:S216-8. 2005
  13. ncbi request reprint First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results
    E Voigt
    Department of Internal Medicine I, University of Bonn, Germany
    HIV Med 3:277-82. 2002
    ..To evaluate safety and efficacy of the protease inhibitor combination ritonavir/indinavir 100/800 mg twice daily plus 2-3 nucleoside reverse transcriptase inhibitors (NRTI) in antiretroviral-naive patients...
  14. ncbi request reprint Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients
    Martin Vogel
    Department of Internal Medicine I, University of Bonn, Germany
    Liver Transpl 10:939-44. 2004
    ..Because of the flat absorption/elimination profiles under ritonavir-boosted HAART cyclosporine A, dosing could be reliably monitored long term by measuring cyclosporine A trough-levels...
  15. doi request reprint How important is HIV therapy for preventing liver fibrosis progression in HIV-HCV-coinfected individuals?
    Jürgen Kurt Rockstroh
    Department of Internal Medicine I, University Hospital Bonn, Bonn, Germany
    Antivir Ther 17:1223-5. 2012
    ....
  16. ncbi request reprint T(H)1 to T(H)2 shift of cytokines in peripheral blood of HIV-infected patients is detectable by reverse transcriptase polymerase chain reaction but not by enzyme-linked immunosorbent assay under nonstimulated conditions
    M Altfeld
    Department of Internal Medicine I, University of Bonn, Germany
    J Acquir Immune Defic Syndr 23:287-94. 2000
    ..Therefore, we determined tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta (IL-1beta), IL-4, IL-10, and interferon-gamma (IFN-gamma) mRNA and serum levels in HIV-infected patients under nonstimulated conditions...
  17. ncbi request reprint Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment
    Oliver Schildgen
    Institut fur Medizinische Mikrobiologie und Immunologie, Universitat Bonn, 53105 Bonn, Germany
    AIDS 18:2325-7. 2004
    ..In all cases adefovir was replaced by tenofovir, resulting in a significant drop in the viral load...
  18. ncbi request reprint Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy
    J K Rockstroh
    Department of Medicine, Sigmund Freud Strasse 25, D 53105 Bonn, Germany
    Eur J Med Res 4:271-4. 1999
    ..Our data suggest that HIV-infected patients resistant to indinavir or ritonavir and double NRTI combination therapy respond to double PI nelfinavir/saquinavir and D4T rescue therapy only initially but have no sustained benefit...
  19. ncbi request reprint Pilot study of interferon alpha high-dose induction therapy in combination with ribavirin for chronic hepatitis C in HIV-co-infected patients
    Jürgen Kurt Rockstroh
    Department of Medicine I, University of Bonn, Germany
    AIDS 16:2083-5. 2002
    ..In HIV/HCV-co-infected patients, the therapeutic benefit of high-dose IFN-alpha therefore seems to be limited by its poor tolerability...
  20. ncbi request reprint [Chronic HIV infection. Current therapeutic aspects]
    M Vogel
    Medizinische Klinik und Poliklinik I, Universitatsklinikum Bonn, Sigmund Freud Str 25, 53127 Bonn
    Internist (Berl) 48:519-24; quiz 525. 2007
    ..Each patient should be counseled according to present treatment guidelines on when and how to start HAART, taking into account the surrogate markers CD4-cell count and HIV-RNA as well as clinically apparent HIV-associated disease...
  21. ncbi request reprint Decrease of elevated N,N-dimethylglycine and N-methylglycine in human immunodeficiency virus infection during short-term highly active antiretroviral therapy
    M P Look
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Metabolism 50:1275-81. 2001
    ....
  22. ncbi request reprint Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy
    M Lichterfeld
    Department of General Internal Medicine, Rheinische Friedrich Wilhems Universität Bonn, Bonn, Germany
    Eur J Med Res 8:56-60. 2003
    ..5% and 56.7% (p = 0.09) in the respective study cohorts. Ritonavir-boosted protease inhibitors therefore seem to induce a superior virological response rate and a higher degree of sustained virological suppression...
  23. ncbi request reprint Antiretroviral drug toxicity -- a challenge for the hepatologist?
    Ulrich Spengler
    Department of General Internal Medicine I, Universitatsklinikum Bonn, Sigmund Freud Strasse 25, 53105 Bonn, Germany
    J Hepatol 36:283-94. 2002
  24. doi request reprint Acute hepatitis C in patients with HIV
    Christoph Boesecke
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    Semin Liver Dis 32:130-7. 2012
    ..Prevention and screening efforts along with early anti-HCV therapy have to be intensified to allow for control of viral dissemination as the current epidemic of AHC particularly among MSM is still ongoing...
  25. ncbi request reprint Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients: outcome of 7 patients from the Bonn cohort
    Martin Vogel
    Department of Internal Medicine I, University of Bonn, Sigmund Freud Strasse 25, 53127 Bonn, Germany
    Liver Transpl 11:1515-21. 2005
    ..In conclusion, even though preliminary, our data suggest that outcomes after liver transplantation of HIV-infected patients can be improved...
  26. ncbi request reprint Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity
    J C Wasmuth
    Department of Medicine I, University of Bonn, Sigmund Freud Str 25, 53105, Bonn, Germany
    Eur J Clin Pharmacol 63:901-8. 2007
    ..We tested whether dose reduction of IDV guided by therapeutic drug monitoring resulted in improved tolerability without compromising antiviral efficacy...
  27. ncbi request reprint Comparison of indinavir + ritonavir 600 + 100 mg vs. 400 + 100 mg BID combinations in HIV1-infected patients guided by therapeutic drug monitoring
    J C Wasmuth
    Department of Medicine I, University of Bonn, Sigmund Freud Str 25, 53105 Bonn, Germany
    Eur J Med Res 12:289-94. 2007
    ..To compare two reduced dose indinavir (IDV) + ritonavir (RTV) combinations guided by therapeutic drug monitoring (TDM) in treatment-naive HIV1-infected patients...
  28. ncbi request reprint [Therapy of hepatitis B and hepatitis C coinfection in HIV patients]
    M Vogel
    Medizinische Universitatsklinik I, Bonn
    MMW Fortschr Med 147:56-9. 2005
    ..Thus, HAART should not be withheld from a patient because of hepatitis coinfection. When cirrhosis is present, semiannual prophylactic checkups are recommended to monitor the occurrence of hepatocellular carcinoma...
  29. ncbi request reprint Should HIV/HCV coinfected patients with severe hepatitis be treated for hepatitis C
    J K Rockstroh
    Medizinische Universitatsklinik I, Bonn
    Presse Med 34:1585-8. 2005
    ..IMPACT OF HAART: Antiretroviral treatment seems to have a positive effect on the course of hepatitis C that exceeds its risk of hepatotoxicity...
  30. pmc Transmission of human immunodeficiency virus I drug resistance - a case report. What are the clinical implications?
    E Anadol
    Department of General Internal Medicine, University of Bonn, Sigmund Freud Strasse 25, 53105 Bonn, Germany
    Eur J Med Res 15:225-30. 2010
    ..Alternatively, this effect could be explained with a different antiviral potency for the respective PIs used...
  31. doi request reprint European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults
    J K Rockstroh
    Department of Medicine I, University of Bonn, Bonn, Germany
    HIV Med 9:82-8. 2008
    ..With the introduction of new agents for the treatment of hepatitis B and increased knowledge of how best to manage hepatitis C, an update of current guidelines for management of HBV and HCV coinfection with HIV is warranted...
  32. ncbi request reprint Malignant thymoma: current status of classification and multimodality treatment
    I G H Schmidt-Wolf
    Medizinische Klinik und Poliklinik I, Rheinische Friedrich Wilhelms Universitat, Sigmund Freud Str 25, 53105 Bonn, Germany
    Ann Hematol 82:69-76. 2003
    ..In this review, a pathologist, an immunologist, a surgeon, a radiotherapist, a pneumologist, and oncologists discuss the current status of classification and strategies for the treatment of patients with thymoma...
  33. ncbi request reprint [Rational use of modern substances for the treatment of HIV-infection]
    J K Rockstroh
    Medizinische Klinik und Poliklinik I, Universitatsklinikum Bonn, Bonn, Deutschland
    Internist (Berl) 49:1463-4, 1466-9. 2008
    ..The significance of new drugs in the clinical setting will be defined more precisely in the near future, as all new substances have been licensed for pre-treated patients only so far...
  34. ncbi request reprint Prediction of imminent complications in HIV-1-infected patients by markers of lymphocyte apoptosis
    J C Wasmuth
    Department of General Internal Medicine, University of Bonn, Germany
    J Acquir Immune Defic Syndr 23:44-51. 2000
    ..The aim of the study was to compare accepted surrogate markers of HIV disease progression with markers of lymphocyte apoptosis in their ability to predict short-term disease progression...
  35. ncbi request reprint [Progressive multifocal leukoencephalopathy]
    J C Wasmuth
    Universitätsklinik Bonn
    Med Klin (Munich) 94:264-73. 1999
    ..Loss of T-helper-cells in the course of HIV-infection or other immunosuppressive states result in reactivation of JC-virus...
  36. ncbi request reprint Antigen-specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus-coinfected patients
    R P Woitas
    Department of Internal Medicine I, University of Bonn, Germany
    AIDS 13:1313-22. 1999
    ..Epidemiological data indicate that hepatitis C virus (HCV) infection runs a more rapid and severe course of disease in HIV-coinfected patients, probably because of an altered immune response...
  37. ncbi request reprint Influence of protease inhibitor therapy on lipoprotein metabolism
    H K Berthold
    Department of Internal Medicine I, University of Bonn, Germany
    J Intern Med 246:567-75. 1999
    ....
  38. ncbi request reprint [Orthotopic liver transplantation in a 33-year-old patient with fulminant hepatitis B and HIV infection]
    K Schliefer
    Medizinische Klinik und Poliklinik I, Universitat Bonn
    Dtsch Med Wochenschr 125:523-6. 2000
    ..A 33-year-old man with fulminant hepatitis B infection was to have an orthotopic liver transplantation (OLTX) because of the otherwise poor prognosis. During preparations for it he was found also to have an HIV-infection...
  39. ncbi request reprint Semiquantitation of human chemokine mRNA levels with a newly constructed multispecific competitor fragment
    F L Dumoulin
    Department of General Internal Medicine, University of Bonn, Germany
    J Immunol Methods 224:61-7. 1999
    ..The assay should be useful for further studies, in particular for the semiquantitation of chemokine mRNA species from small cell or tissue specimens...
  40. ncbi request reprint Semi-quantification of human C-C chemokine mRNAs with reverse transcription/real-time PCR using multi-specific standards
    F L Dumoulin
    Department of Medicine I, University of Bonn, Germany
    J Immunol Methods 241:109-19. 2000
    ..The method was successfully applied to the semi-quantification of chemokines in human liver specimens and should be useful in further studies on steady state mRNA levels of C-C chemokines from low cell numbers or small tissue specimens...
  41. ncbi request reprint Parallel decrease in neurotoxin quinolinic acid and soluble tumor necrosis factor receptor p75 in serum during highly active antiretroviral therapy of HIV type 1 disease
    M P Look
    Department of General Internal Medicine, University of Bonn, Germany
    AIDS Res Hum Retroviruses 16:1215-21. 2000
    ..This eventually led to a decrease in quinolinic acid formation. The parallel reduction of the immune activation marker sTNFR p75 supports this hypothesis...
  42. ncbi request reprint Painful multifocal arthritis: therapy with rhenium 186 hydroxyethylidenediphosphonate ((186)Re HEDP) after failed treatment with medication--initial results of a prospective study
    H Palmedo
    Department of Nuclear Medicine, University of Bonn, Sigmund Freud Strasse 25, 53105 Bonn, Germany
    Radiology 221:256-60. 2001
    ..In six (75%) of eight patients, a single injection of (186)Re HEDP led to an improvement in disease activity. Systemic low-dose treatment with (186)Re HEDP can reduce pain and disease activity in patients with polyarthritis...
  43. ncbi request reprint Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results
    E Voigt
    Department of Internal Medicine, University of Bonn, Sigmund Freud Str 25, D 53105, Bonn, Germany
    Infection 32:82-8. 2004
    ..Within this open-label, uncontrolled prospective trial we evaluated safety, efficacy and development of genotypic resistance under the new protease inhibitor lopinavir/ritonavir (LPV/r) in antiretroviral (ARV) HIV patients...
  44. ncbi request reprint Changes of lymphocyte apoptosis associated with sequential introduction of highly active antiretroviral therapy
    J C Wasmuth
    Department of Internal Medicine I, University of Bonn, Germany
    HIV Med 4:111-9. 2003
    ..To assess the effect of highly active antiretroviral therapy (HAART) on surrogate markers of lymphocyte apoptosis in HIV 1-infected individuals...
  45. ncbi request reprint Enteric dysfunction in patients with asymptomatic HIV-infection versus patients with hypoproteinemia/hypalbuminemia and advanced HIV-infection
    J C Wasmuth
    Department of Internal Medicine I, University of Bonn, Germany
    Eur J Med Res 7:536-42. 2002
    ..It is unclear whether enteric dysfunction and protein losses contribute to hypoproteinemia, which heralds poor survival in HIV infection...
  46. ncbi request reprint [Do polymorphisms of the SDF1 and CCR2b genes modify the course of hepatitis C or HIV/HCV co-infection?]
    R P Woitas
    Medizinische Klinik und Poliklinik I, Hugstetter, Freiburg, Germany
    Dtsch Med Wochenschr 127:1807-12. 2002
    ..While the CCR5-Delta32 mutation is also increased in chronic hepatitis C virus (HCV) infection it is unclear, whether the CCR2b-V64 I and the SDF-1 3'A polymorphisms also are associated with chronic HCV infection...
  47. ncbi request reprint New aspects in the treatment of AIDS-related lymphoma
    I G H Schmidt-Wolf
    Medizinische Universitätsklinik und Poliklinik I, Rheinische Friedrich Wilhelms Universitat, Bonn, Germany
    Eur J Med Res 7:295-303. 2002
    ..It is hoped that novel strategies will lead to a survival benefit in these patients. In this review, we discuss the current strategies for the treatment of AIDS-related lymphoma...
  48. ncbi request reprint Sodium selenite and N-acetylcysteine in antiretroviral-naive HIV-1-infected patients: a randomized, controlled pilot study
    M P Look
    Department of General Internal Medicine, University of Bonn, Germany
    Eur J Clin Invest 28:389-97. 1998
    ....
  49. ncbi request reprint [Splenic infarct in a patient with HIV infection]
    Jan Christian Wasmuth
    Medizinische Klinik und Poliklinik, Immunologische Ambulanz, Universitatsklinikum Bonn, Sigmund Freud Strasse 25, 53105 Bonn
    Med Klin (Munich) 100:683-5. 2005
  50. doi request reprint Diagnosis and treatment of acute hepatitis C virus infection
    Christoph Boesecke
    Department of Internal Medicine I, Bonn University Hospital, Sigmund Freud Strase 25, 53105 Bonn, Germany
    Infect Dis Clin North Am 26:995-1010. 2012
    ..This article addresses similarities and differences in the epidemiology, diagnosis, and management of AHC monoinfection and coinfection...
  51. doi request reprint Vicriviroc, a new CC-chemokine receptor 5 inhibitor for treatment of HIV: properties, promises and challenges
    Johannes Carl Christoph Lenz
    University of Bonn, Medicine I, Sigmund Freudstr 25, Bonn 53105, Germany
    Expert Opin Drug Metab Toxicol 6:1139-50. 2010
    ..CCR5 inhibitors are believed to possibly decrease inflammation from the immune system and thereby offer additional properties further to their antiretroviral efficacy...
  52. doi request reprint Hot topics in HIV and hepatitis coinfection: noninvasive diagnosis of liver disease, liver transplantation, and new drugs for treatment of hepatitis coinfection
    Jürgen Kurt Rockstroh
    Department of Medicine, University of Bonn, Bonn, Germany
    HIV Clin Trials 10:110-5. 2009
    ....
  53. ncbi request reprint Lymphoid pneumonitis as an immune reconstitution inflammatory syndrome in a patient with CD4 cell recovery after HAART initiation
    P Ingiliz
    Department of Medicine I, University of Bonn, Bonn, Germany
    HIV Med 7:411-4. 2006
    ..He improved dramatically after treatment with oral steroids...
  54. doi request reprint Drug safety evaluation of maraviroc for the treatment of HIV infection
    Jan Christian Wasmuth
    Universitatsklinikum Bonn, Medical Department I, Sigmund Freud Str 25, 53105 Bonn, Germany
    Expert Opin Drug Saf 11:161-74. 2012
    ..Maraviroc is the only C-chemokine receptor 5 (CCR5) antagonist approved for the treatment of infection with HIV. This article reviews the safety and efficacy of maraviroc in the treatment of HIV infection...
  55. doi request reprint S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges
    Johannes Carl Christoph Lenz
    University of Bonn, Medicine I, Bonn, Germany
    Expert Opin Investig Drugs 20:537-48. 2011
    ..Phase II studies in INI-experienced patients show partially retained activity in vivo. Overall, the safety profile of S/GSK1349572 in all studies completed has been very favorable...
  56. ncbi request reprint CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature
    J M Emmelkamp
    Department of Medicine I, University Clinic Bonn, Sigmund Freud Str 25, 53105 Bonn, Germany
    Eur J Med Res 12:409-17. 2007
    ..Extended follow-up of the vicriviroc trials showed no further case of malignancy, reassuring the overall good tolerability profile of the drug so far...
  57. ncbi request reprint Elevated serum activity of N-acetyl-beta-glucosaminidase in essential hypertension: diagnostic value and reversal to normal values after antihypertensive therapy
    R E Schmieder
    Department of Medicine, University of Bonn, Bonn Venusberg, Germany
    Am J Kidney Dis 18:638-48. 1991
    ..We conclude that in patients with mild essential hypertension, serum NAG activity was already elevated (whereas urinary NAG activity was not) and was normalized by effective antihypertensive treatment.(ABSTRACT TRUNCATED AT 400 WORDS)..
  58. ncbi request reprint Determination of nevirapine in plasma by GC-MS
    M Vogel
    Department of Internal Medicine I, Bonn University, Bonn, Germany
    J Chromatogr Sci 48:91-4. 2010
    ..GC-MS proved to be a valid alternative to high-performance liquid chromatography and liquid chromatography-MS...